Organogenesis Holdings Inc. Class A Common Stock (ORGO) Stock Price

ORGOStock

$1.00−75.38%52W

Market Cap$128.64M

P/E3.47x

PEG Ratio6.54

Div yield—

Beta1.45

ORGO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-70.08%

Price vs S&P 500 (4W)-27.27%

PEG Ratio6.54

VGM Score53.14

P/E Ratio (Annual)3.47x

P/CF (Annual)28.67x

Book Value / Share (Quarterly)$2.24

P/TBV (Annual)1.55x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)7.76%

Cash Flow / Share (Quarterly)$0.16

Price vs S&P 500 (YTD)-92.63%

Gross Margin (TTM)70.35%

Net Profit Margin (TTM)-18.40%

EPS (TTM)$-0.69

10-Day Avg Trading Volume0.83M

EPS Excl Extra (TTM)$-0.69

Revenue Growth (5Y)10.77%

EPS (Annual)$0.28

ROI (Annual)8.12%

Gross Margin (Annual)75.62%

Net Profit Margin (5Y Avg)6.32%

Cash / Share (Quarterly)$0.36

P/E Basic Excl Extra (TTM)84.95x

Revenue Growth QoQ (YoY)-56.68%

EPS Growth (5Y)12.99%

P/E Normalized (Annual)3.47x

ROA (Last FY)6.19%

Revenue Growth TTM (YoY)6.50%

EBITD / Share (TTM)$-0.15

ROE (5Y Avg)11.11%

Operating Margin (TTM)-7.84%

Cash Flow / Share (Annual)$-0.19

P/B Ratio0.45x

P/B Ratio (Quarterly)1.09x

Net Income / Employee (Annual)$43,400

EV / Revenue (TTM)0.21x

Net Interest Coverage (TTM)-0.82x

ROA (TTM)-16.54%

EPS Growth QoQ (YoY)423.65%

EV / EBITDA (TTM)5.08x

EPS Incl Extra (Annual)$0.28

Current Ratio (Annual)3.62x

Quick Ratio (Quarterly)2.66x

3-Month Avg Trading Volume0.77M

52-Week Price Return-75.38%

EV / Free Cash Flow (Annual)83.08x

P/E Incl Extra (TTM)84.95x

Revenue / Employee (TTM)$535,700

Tangible BV / Share (Quarterly)$2.22

P/S Ratio (Annual)0.23x

Asset Turnover (Annual)0.94x

52-Week High$7.08

Operating Margin (5Y Avg)6.13%

EPS Excl Extra (Annual)$0.28

CapEx CAGR (5Y)-4.36%

Tangible BV CAGR (5Y)29.75%

26-Week Price Return-60.17%

Quick Ratio (Annual)3.14x

13-Week Price Return-61.84%

Total Debt / Equity (Annual)0.05x

Current Ratio (Quarterly)3.52x

Enterprise Value$94.22M

Revenue / Share Growth (5Y)7.36%

Asset Turnover (TTM)0.90x

Book Value / Share Growth (5Y)24.47%

Revenue / Employee (Annual)$660,600

Inventory Turnover (Annual)4.92x

Pretax Margin (Annual)8.33%

Cash / Share (Annual)$0.74

3-Month Return Std Dev68.20%

Gross Margin (5Y Avg)75.87%

Net Income / Employee (TTM)$-98,500

EBITDA CAGR (5Y)12.46%

EBITDA Interim CAGR (5Y)24.16%

ROE (Last FY)8.53%

Net Interest Coverage (Annual)-6.05x

EPS Basic Excl Extra (Annual)$0.28

P/FCF (TTM)2.40x

Receivables Turnover (TTM)4.13x

EV / Free Cash Flow (TTM)4.52x

Total Debt / Equity (Quarterly)0.04x

EPS Incl Extra (TTM)$-0.69

Receivables Turnover (Annual)3.45x

ROI (TTM)-21.87%

P/S Ratio (TTM)0.28x

Pretax Margin (5Y Avg)5.66%

Revenue / Share (Annual)$4.33

Tangible BV / Share (Annual)$3.35

Forward P/E21.65x

Price vs S&P 500 (52W)-90.91%

P/E Ratio (TTM)84.95x

EPS Growth TTM (YoY)3600.00%

Year-to-Date Return-80.70%

5-Day Price Return-18.72%

EPS Normalized (Annual)$0.28

ROA (5Y Avg)6.46%

Net Profit Margin (Annual)6.56%

Month-to-Date Return-27.03%

Cash Flow / Share (TTM)$0.20

EBITD / Share (Annual)$0.46

EPS Growth (3Y)34.40%

Operating Margin (Annual)7.92%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)4.02x

ROI (5Y Avg)8.89%

P/E Excl Extra (TTM)84.95x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.69

P/TBV (Quarterly)1.10x

P/B Ratio (Annual)1.51x

Inventory Turnover (TTM)4.35x

Pretax Margin (TTM)-7.60%

Book Value / Share (Annual)$3.42

Price vs S&P 500 (13W)-64.53%

Net Margin Growth (5Y)5.25%

Beta1.45x

P/FCF (Annual)30.80x

Revenue / Share (TTM)$3.56

ROE (TTM)-22.60%

52-Week Low$0.99

vGradeB

gGradeB

mGradeF

vgmGradeC

ORGO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.35	-$0.69	-97.66%(-$0.34)
Q1 2026	May 7, 2026	-$0.29	-$0.34	-18.03%(-$0.05)
Q4 2025	Feb 26, 2026	$0.21	$0.40	+90.52%(+$0.19)
Q3 2025	Nov 6, 2025	$0.07	$0.18	+153.57%(+$0.11)
Q2 2025	Aug 7, 2025	-$0.01	-$0.06	-491.00%(-$0.05)

ORGO Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

2.29

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ORGOOrganogenesis Holdings Inc. Class A Common Stock	B	B	F	0.3x	6.5%	70.3%	13.0%	$1.00
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Organogenesis Holdings Inc. Class A Common Stock

Organogenesis is a regenerative medicine company specializing in advanced wound care, surgical, and sports medicine markets. The company develops and commercializes bioengineered tissue products designed to accelerate healing and improve surgical outcomes. Its portfolio includes solutions for chronic wound management, acute surgical applications, and soft tissue repair across hospital and outpatient settings.